Response to: Comment on “Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)” 27 de May de 2025 by Galarza Fortuna, G. M., Swami, U., Gupta, S.
